Country: Canada
Language: English
Source: Health Canada
BUPROPION HYDROCHLORIDE
BAUSCH HEALTH, CANADA INC.
N06AX12
BUPROPION
150MG
TABLET (EXTENDED-RELEASE)
BUPROPION HYDROCHLORIDE 150MG
ORAL
100
Prescription
MISCELLANEOUS ANTIDEPRESSANTS
Active ingredient group (AIG) number: 0131140003; AHFS:
APPROVED
2021-06-14
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR BUPROPION HCL SR Bupropion Hydrochloride Sustained-Release Tablets Tablets (sustained-Released), 150mg, for oral use Mfr. Std. ANTIDEPRESSANT DATE OF INITIAL AUTHORIZATION: JUN 14, 2021 DATE OF REVISION: JUN 01, 2023 BAUSCH HEALTH, CANADA INC. 2150 St-Elzear Blvd. West Laval, Quebec H7L 4A8 Control No.: 273964 _Pr_ _BUPROPION HCL SR Product Monograph _ _Page 2 of 44 _ RECENT MAJOR LABEL CHANGES 3 SERIOUS WARNINGS AND PRECAUTIONS BOX 7 WARNING AND PRECAUTIONS, Immune TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ................................................................. 4 1 INDICATIONS ................................................................................................................. 4 1.1 Pediatrics .............................................................................................................. 4 1.2 Geriatrics ............................................................................................................... 4 2 CONTRAINDICATIONS .................................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX........................................................ 5 4 DOSAGE AND ADMINISTRATION ................................................................................ 5 4.1 Dosing Considerations ........................................................................................... 5 4.2 Recommended Dose and Dosage Adjustment....................................................... 5 4.4 Administration ........................................................................................................ 6 4.5 Missed Dose......................................................................................... Read the complete document